Off-label use of maraviroc in clinical practice.

about

Off-label use of maraviroc in clinical practice.

Item

http://www.wikidata.org/entity/Q42654565

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Off-label use of maraviroc in clinical practice.

@en

Off-label use of maraviroc in clinical practice.

@nl

type

Item

label

Off-label use of maraviroc in clinical practice.

@en

Off-label use of maraviroc in clinical practice.

@nl

prefLabel

Off-label use of maraviroc in clinical practice.

@en

Off-label use of maraviroc in clinical practice.

@nl

P1476

Off-label use of maraviroc in clinical practice

@en

P2093

José-Ramón Blanco

http://www.w3.org/2001/XMLSchema#string

Laura Ochoa-Callejero

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and functional expression of a new human CC-chemokine receptor gene

Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients

Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis

Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-a

Chemokines: attractive mediators of the immune response.

P304

5-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/14787210.2016.1100535

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Laura Ochoa-callejero

Jose-Ramon Blanco

P577

2015-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283305645

http://www.w3.org/2001/XMLSchema#string

P698

26509356

http://www.w3.org/2001/XMLSchema#string